| 0.9833 0.005 (0.48%) | 12-07 15:57 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.41 | 1-year : | 1.74 |
| Resists | First : | 1.21 | Second : | 1.49 |
| Pivot price | 0.91  |
|||
| Supports | First : | 0.76 | Second : | 0.63 |
| MAs | MA(5) : | 0.95 |
MA(20) : | 0.89 |
| MA(100) : | 1.48 |
MA(250) : | 3.92 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 28.1 |
D(3) : | 26.2 |
| RSI | RSI(14): 50.3 |
|||
| 52-week | High : | 18.36 | Low : | 0.76 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ENSC ] has closed below upper band by 28.8%. Bollinger Bands are 32.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1 - 1.01 | 1.01 - 1.01 |
| Low: | 0.96 - 0.96 | 0.96 - 0.96 |
| Close: | 0.98 - 0.98 | 0.98 - 0.99 |
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Fri, 01 Dec 2023
Should You Buy Ensysce Biosciences Inc (ENSC) Stock Friday Morning? - InvestorsObserver
Tue, 28 Nov 2023
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the ... - Yahoo Finance
Thu, 16 Nov 2023
Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study - Ensysce Biosciences (N - Benzinga
Tue, 24 Oct 2023
Ensysce Biosciences Secures $1.7 Million Convertible Note Financing - Yahoo Finance
Wed, 18 Oct 2023
Is Ensysce Biosciences Inc (ENSC) Stock at the Top of the Biotechnology Industry? - InvestorsObserver
Tue, 17 Oct 2023
Premarket Mover: Ensysce Biosciences Inc (ENSC) Down 11.41% - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 5.9 (%) |
| Shares Short | 68 (K) |
| Shares Short P.Month | 23 (K) |
| EPS | -1.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.51 |
| Profit Margin | 0 % |
| Operating Margin | -621.9 % |
| Return on Assets (ttm) | -149.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 55.9 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.53 |
| PEG Ratio | 0 |
| Price to Book value | 1.89 |
| Price to Sales | 0.98 |
| Price to Cash Flow | -0.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|